Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases
Advanced Drug Delivery Reviews · 2025
DOI: 10.1016/j.addr.2025.115525 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025. Verfasst von Michal Izrael und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel. Electronic address: Michal.Izrael@…. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Pluripotent Stem Cells, Cell- and Tissue-Based Therapy, Stem Cell Transplantation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 146 Literaturangaben.
Abstract (Originalsprache)
Self-renewal capacity and potential to differentiate into almost any cell type of the human body makes pluripotent stem cells a valuable starting material for manufacturing of clinical grade cell therapies. Neurodegenerative diseases are characterized by gradual loss of structure or function of neurons, often leading to neuronal death. This results in gradual decline of cognitive, motor, and physiological functions due to the degeneration of the central nervous systems. Over the past two decades, comprehensive preclinical efficacy (proof-of-concept) and safety studies have led to the initiation of First-in-Human phase I-II clinical trials for a range of neurodegenerative diseases. In this review, we explore the fundamentals and challenges of neural-cell therapies derived from pluripotent stem cells for treating neurodegenerative diseases. Additionally, we highlight key preclinical investigations that paved the way for regulatory approvals of these trials. Furthermore, we provide an overview on progress and status of clinical trials done so far in treating neurodegenerative diseases such as spinal cord injury (SCI), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), as well as advances in retina diseases such as Stargardt disease (a.k.a fundus flavimaculatus), retinitis pigmentosa (RP) and age-related macular degeneration (AMD). These trials will pave the way for the development of new cell-based therapies targeting additional neurological conditions, including Alzheimer's disease and epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel. Electronic address: Michal.Izrael@mail.huji.ac.il.
- Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.
- Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel; Department of Molecular Genetics, Weizmann Institute of Science, 76100, Rehovot, Israel.
Zitieren
APA
Izrael, M., Chebath, J., Molakandov, K., & Revel, M. (2025). Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2025.115525
Vancouver
Izrael M, Chebath J, Molakandov K, Revel M. Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases. Advanced Drug Delivery Reviews. 2025. doi:10.1016/j.addr.2025.115525
BibTeX
@article{Izrael2025,
author = {Izrael, Michal and Chebath, Judith and Molakandov, Kfir and Revel, Michel},
title = {Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases},
journal = {Advanced Drug Delivery Reviews},
year = {2025},
doi = {10.1016/j.addr.2025.115525}
}
EUVIMED